Hydration Pharmaceuticals Company Limited · ASX:HPC
Hydration Pharmaceuticals — The Hydration Pharmaceuticals Company — Shareholder Meeting (May 2025)
9 slides from Hydration Pharmaceuticals's shareholder meeting presentation, May 28, 2025
Slide 1: November Strategy Meeting AGM + 2025 Outlook
For personal use only November Strategy Meeting AGM + 2025 Outlook 1
Slide 2: 2024 Highlights
2 2024 Highlights For personal use only ● Market cap fell well below intrinsic company value, A$3-6m, during 2024. Combined with low liquidity plus our debt relative th ow n to market cap meant that securing a sale was by far the best De let g r U etio ion SK ccr course of action to return value to
Slide 3: Q1 2025 Quarterly Results
3 Q1 2025 Quarterly Results For personal use only ● Q1 net sales of US$720,177, up 16% on PCP on a normalised basis, adjusting for discontinued SKUs and remaining range following non-US asset sale ● Quarterly sales consistent with annualised net revenue rate of US$3m-US$3.5m; growth underpinned by b
Slide 4: Looking Ahead: HydraLyte Territory Value History and US go-forward
4 Looking Ahead: HydraLyte Territory Value History and US go-forward For personal use only Sale of Australia/NZ 2014 for ~US$80m. Subsequent creation and IPO of Hydralyte International, now USA only HPC:ASX. Canada + ROW sold October 2024 for ~US$9.5m / Company focus is now USA only Canada + ROW (so
Slide 5: Company performance before sale of Non-USA territories
5 Company performance before sale of Non-USA territories For personal use only 2019 2020 2021 2022 2023 2019 2020 2021 2022 2023
Slide 6: US standalone sales snapshot
For personal use only US standalone sales snapshot Breakdown on Q1 run rate of ~$US3.5m in net sales Low focus vs Amazon Legacy SKUs / Low growth High Growth Our current and continued focus
Slide 7: +183% Growth Over Years
+183% Growth Over 2 Years Liver Support +183% Growth over 2 Years For personal use only In market: $35k a week on Amazon +40% YTD Growth EL - Update Electrolytes + Detox Inventory Constraints 18 Ingredients Inc. Milk Thistle
Slide 8: US products have evolved to meet consumer & category
US products have evolved to meet consumer & category For personal use only HydraLyte at the intersection of daily rehydration and drinkable vitamins - leading industry innovation Original Products from AUS / CA US growth drivers COMING SEP QUARTER HydraLyte Plus Liver Support 7 Key Electrolytes 6 An
Slide 9: What matters
9 What matters For personal use only Sales ($USD) Cash ($USD) Future Base US$3-3.5m New and existing US$2.4m in bank, (+16% on same SKU) SKUs with improving ~US$700k current Best SKU +40% margin profile, more $ quarter and declining growth cuts already made
The Hydration Pharmaceuticals Company — Shareholder Meeting (May 2025) on 6ix